Last reviewed · How we verify
Normoxic Allogenic UCMSC
At a glance
| Generic name | Normoxic Allogenic UCMSC |
|---|---|
| Sponsor | Kementerian Riset dan Teknologi / Badan Riset dan Inovasi Nasional, Indonesia |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Allogenic UCMSCs as Adjuvant Therapy for Severe COVID-19 Patients (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: